Last updated: February 20, 2026
Who Are the Primary Suppliers of Zokinvy (mirovirsen)?
Zokinvy (mirovirsen) is an antisense oligonucleotide developed for the treatment of Hutchinson-Gilford progeria syndrome (HGPS). It is marketed by Eiger BioPharma. The production of Zokinvy involves specialized manufacturing processes for oligonucleotide synthesis, purification, and formulation.
The key suppliers in the Zokinvy supply chain can be categorized as follows:
Active Pharmaceutical Ingredient (API) Suppliers
- BioSpring GmbH: Provides custom oligonucleotide synthesis, including sequence-specific synthesis, scale-up, and purification services.
- Eurofins Genomics: Supplies oligonucleotide building blocks, primers, and custom oligonucleotides used in Zokinvy production.
- Sigma-Aldrich (Merck): Offers phosphoramidites and other synthesis reagents necessary for manufacturing antisense oligonucleotides.
Manufacturing Partners
- Samsung Biologics: Contract manufacturer known for biologics; not directly involved in Zokinvy but potential partner or comparable capacity provider for oligonucleotide manufacturing.
- Fujifilm Diosynth Biotechnologies: Has a history of producing complex oligonucleotides through proprietary processes, although specific involvement with Zokinvy has not been publicly disclosed.
- Q-Gen Cell Sciences (GeneSys): Specializes in oligonucleotide manufacturing, potentially supplying for clinical or commercial batches.
Formulation and Final Product Manufacturing
- Catalent Inc.: Provides formulation, fill-finish, and packaging services for oligonucleotide-based therapeutics.
- Roxane Laboratories (part of Konica Minolta): Engages in manufacturing final drug products, including specialized handling for antisense oligonucleotides.
Supply Chain Specifics and Constraints
- The manufacturing of antisense oligonucleotides like Zokinvy requires high purity, specific modifications, and controlled conditions, limiting the list of competent suppliers.
- Patent rights and proprietary synthesis techniques can restrict direct access to certain supplier sources or manufacturing processes.
- Most suppliers are located in North America and Europe, with few options globally for raw oligonucleotide synthesis at the scale required for commercial production.
Market and Regulatory Considerations
- Zokinvy received FDA approval in November 2020 and EMA approval later in 2021.
- The supply chain experienced disruptions during initial launch phases, attributable to high demand and complex manufacturing.
Conclusion
Zokinvy's supply primarily depends on specialized oligonucleotide synthesis companies, with key players being BioSpring GmbH, Eurofins Genomics, and Sigma-Aldrich. Contract manufacturing organizations such as Catalent and Roxane are involved in formulation and final product assembly. Consistency of supply relies on high-purity synthesis, rigorous quality controls, and limited number of capable suppliers.
Key Takeaways
- Zokinvy's primary supplies involve custom oligonucleotide synthesis, with BioSpring GmbH and Eurofins Genomics as top providers.
- Contract manufacturers like Catalent play a critical role in formulation and packaging.
- Supply chain constraints center on complex oligonucleotide production requirements and proprietary synthesis methods.
- The global supply of antisense oligonucleotides is concentrated among a few specialized companies.
FAQs
1. Are there alternatives to BioSpring GmbH for oligonucleotide synthesis for Zokinvy?
Limited options exist for high-quality, GMP-compliant oligonucleotide synthesis at the required scale. Companies like Eurofins and Sigma-Aldrich present alternatives, but their capacity and qualifications differ.
2. How has supply chain disruption affected Zokinvy availability?
Disruptions during initial launch caused delays and shortages owing to high demand and manufacturing complexity. These have since stabilized as suppliers scaled up production.
3. What are the main challenges in sourcing raw materials for Zokinvy?
The synthesis reagents, such as phosphoramidites, are specialized and subject to supply constraints. Their procurement depends on global supply chain stability and proprietary restrictions.
4. Do regulatory guidelines impact supplier choice for Zokinvy?
Yes. Suppliers must meet GMP standards, and their manufacturing processes are scrutinized during regulatory review. Proprietary methods also influence selection.
5. Is there patent protection affecting new suppliers entering the Zokinvy production chain?
Yes. Patents on specific oligonucleotide modifications and synthesis techniques limit entry of new suppliers and enforce exclusivity among current manufacturers.
References
- U.S. Food and Drug Administration (FDA). (2020). Zokinvy Approval Letter.
- European Medicines Agency (EMA). (2021). Summary of Product Characteristics for Zokinvy.
- BioSpring GmbH. (2022). Custom Oligonucleotide Synthesis Services.
- Eurofins Genomics. (2022). Oligonucleotide Manufacturing Capabilities.
- Sigma-Aldrich (Merck). (2022). Phosphoramidite Supplies for Oligonucleotide Synthesis.
